Table 4.
Diagnostic performance of the eazyplex® SARS-CoV-2 assay for prospective analysis of nasal and oropharyngeal swabs in comparison to NeuMoDx™ RT-PCR.
| NeuMoDx™ | eazyplex® |
PPA, % (CI) | NPA, % (CI) | PPV, % | NPV, % (CI) | |||
|---|---|---|---|---|---|---|---|---|
| Positive | Negative | Total | ||||||
| All Ct values | Positive | 16 | 8 | 24 | 66.7 (44.7−84.4) | 100 (98.8−100) | 100 | 93 (88.3−95.9) |
| Negative | 0 | 106 | 106 | |||||
| Total | 16 | 114 | 130 | |||||
| Ct values ≤30a | Positive | 16 | 3 | 19 | 84.2 (60.4−96.6) | 100 (96.6−100) | 100 | 97.2 (92.6−99) |
| Negative | 0 | 106 | 106 | |||||
| Total | 16 | 109 | 125 | |||||
| Ct values ≤28a | Positive | 13 | 0 | 13 | 100 (76.8−100) | 100 (96.6−100) | 100 | 100 |
| Negative | 0 | 106 | 106 | |||||
| Total | 13 | 106 | 119 | |||||
PPA, positive percent agreement; NPA, negative percent agreement; CI, 95 % confidence interval; PPV, positive predictive value; NPV, negative predictive value.
a
for N or/and Nsp2 gene.